RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.10 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-11-07
- RELMADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.60.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-03-31 was $0.80.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.61, a 64.73% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $7.40, a 65.01% decline from fiscal 2021.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $21.15, a 46.46% decline from fiscal 2020.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $39.50, a 64.58% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-09-30 | $3.10 10-Q · filed 2024-11-07 | |||||
| 2024-06-30 | $3.10 10-Q · filed 2024-08-07 | |||||
| 2023-12-31 | $2.61 10-K · filed 2024-03-19 | |||||
| 2023-09-30 | $3.52 10-Q · filed 2023-11-08 | |||||
| 2023-06-30 | $3.53 10-Q · filed 2023-08-08 | |||||
| 2023-03-31 | $3.60 10-Q · filed 2023-05-11 | |||||
| 2022-12-31 | $7.40 10-K · filed 2024-03-19 | |||||
| 2021-12-31 | $21.15 10-K · filed 2023-03-23 | |||||
| 2020-12-31 | $39.50 10-K · filed 2022-03-25 | $32.45 10-K · filed 2021-03-24 | ||||
| 2019-12-31 | $24.31 10-K · filed 2021-03-24 | $29.32 10-KT · filed 2020-03-26 | $24.00 10-K · filed 2021-03-24 | |||
| 2019-06-30 | $3.84 10-K · filed 2021-03-24 | |||||
| 2018-12-31 | $4.60 10-KT · filed 2020-03-26 | |||||
| 2018-06-30 | $2.64 10-KT · filed 2020-03-26 | $0.66 10-K · filed 2019-09-24 | ||||
| 2015-06-30 | $12.63 10-K · filed 2015-09-11 | |||||
| 2014-06-30 | $7.50 10-K · filed 2015-09-11 | $1.50 10-KT · filed 2014-09-09 | ||||
| 2014-03-31 | $0.80 8-K · filed 2014-05-27 | |||||
| 2013-12-31 | $4.00 10-K · filed 2015-09-11 | $0.08 8-K · filed 2014-05-27 | ||||
| 2012-12-31 | $0.08 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |